COR/SCHERING INTEGRILIN PURSUIT DATA SUPPORT USE WITH ANGIOPLASTY, NOT BROADER CORONARY SYNDROME INDICATION; PHASE IV STUDIES URGED FOR HIGHER DOSE
Executive Summary
Cor Therapeutics' Integrilin PURSUIT data supports use of eptifibatide in patients receiving percutaneous transluminal coronary angioplasty, FDA's Cardiovascular & Renal Drugs Advisory Committee agreed at a meeting Jan. 28.